SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Phase 3

Completed

• Conditions: COVID-19; SARS CoV 2 Infection
• Interventions: Drug: Placebo; Drug: Bemnifosbuvir (BEM)

• Registration Number: NCT05629962
• Lead Sponsor: Atea Pharmaceuticals, Inc.

Brief Summary

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-25
• Study First Submitted: 2022-11-26
• Study First Submitted QC: 2022-11-26
• Study First Posted: 2022-11-29
• Primary Completion: 2024-04-25
• Study Completion: 2024-05-30
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-06
• Last Update Posted: 2024-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2295

Inclusion Criteria

• Positive SARS-CoV-2 test conducted ≤ 5 days prior to randomization

• Mild or moderate COVID-19 with symptom onset ≤ 5 days before randomization and at least one COVID-19 related symptom present at time of screening

• Subject must be high risk, defined below:

  1. Age ≥70 years OR
  2. Age ≥55 years with one of the following: i) obesity (body mass index [BMI] ≥30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR
  3. Age 50 to 54 years with two of the following: i) obesity (BMI ≥30 kg/m2) ii) diabetes mellitus iii) cardiovascular disease or hypertension iv) chronic lung disease requiring routine therapy OR
  4. Age ≥18 years with one of the following: i) Down syndrome, sickle cell disease, dementia, Parkinson's disease, or care home residents ii) One of the following immunocompromising conditions or immunosuppressive treatments: receiving chemotherapy for cancer, hematologic malignancy, being within 2 years of a hematopoietic stem cell transplant, receipt of a solid organ transplant and on immunosuppressive therapy, human immunodeficiency virus (HIV) infection untreated or with CD4+ T lymphocyte count <350 cells per cubic millimeter, moderate/severe primary immunodeficiency, taking immunosuppressive medications

• Use of adequate contraception for females of childbearing potential

Exclusion Criteria

• Severe or critical COVID-19 illness
• Admitted to a hospital within 90 days prior to randomization due to COVID-19
• Use of other investigational drugs within 30 days prior to planned dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study
• Initiation or planned initiation of remdesivir for treatment of the current SARS-CoV-2 infection
• Requirement of prohibited medications, including hydroxychloroquine or amiodarone within 3 months prior to screening. Note: Subjects who had already initiated any COVID-19 drug with antiviral effects intended to treat symptomatic SARS-CoV-2 infection (≥ 24 hours prior to randomization) will be excluded. During screening (or within 24 hours prior to or after randomization), locally available COVID-19 drugs with antiviral effects (including but not limited to nirmatrelvir/ritonavir, molnupiravir, favipiravir, monoclonal antibodies) will be permitted.
• Other known active viral or bacterial infection at the time of screening, such as influenza and respiratory syncytial virus (RSV). Note: This exclusion does not apply to subjects with stable chronic viral infections, such as chronic hepatitis C virus (HCV) or HIV providing other eligibility criteria are met.
• Receiving dialysis or have known severe renal impairment
• History of severe hepatic impairment (Child-Pugh Class C)
• Known allergy or hypersensitivity to components of study drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Bemnifosbuvir (BEM)	Bemnifosbuvir (BEM)	-

Primary Outcome Measures

Name	Time	Method
Proportion of subjects hospitalized for any cause or died due to any cause	Day 1 through Day 29

Secondary Outcome Measures

Name	Time	Method
Proportion of subjects who died due to any cause	Day 1 through Day 29; Day 1 through Day 60
Proportion of subjects with COVID-19-related complications	Day 1 through Day 29
Proportion of subjects hospitalized due to COVID-19 or died due to any cause	Day 1 through Day 29
Proportion of subjects with COVID-19 symptom relapse	Day 1 through Day 29
Proportion of subjects with COVID-19-medically attended visits (hospitalization, emergency room (ER) visit, urgent care visit, physician's office visit, or telemedicine visit) or who died due to any cause	Day 1 through Day 29; Day 1 through Day 60
Proportion of subjects with viral load rebound	Day 1 through Day 29

Trial Locations

Locations (3)

Atea Study site; 🇲🇽 San Luis Potosí, San Luis Potos, Mexico

Atea Study SIte; 🇹🇷 Kayseri, Turkey

Atea Study Site; 🇬🇧 Castleford, West Yourkshire, United Kingdom